194
Participants
Start Date
February 25, 2024
Primary Completion Date
July 24, 2024
Study Completion Date
July 24, 2024
PSNS
The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
ISNS
The nasal spray was self-administered by study subjects at a maximum daily dose of 16 puffs per day, distributed over 1-2 puffs per nostril 2-4 times per day, depending on symptom severity and their alleviation.
Stortorget Øre Nese Hals AS, Hamar
Hov Legesenter, Hov
Heiaklinikken Legesenter, Helsehuset Lierskogen, Lierskogen
Stavanger Øre-Nese-Hals, Stavanger
Sørlandet Sykehus, Kristiansand, Department for Ear, Nose and Throat, Kristiansand
Haukeland Universitetssykehus, Departments of Otolaryngology and Head and Neck Surgery, Helse Bergen, Bergen
Bjørge Øre-Nese-Hals, Ålesund
Lead Sponsor
Proponent Biotech GmbH
UNKNOWN
Pharma Nordic AS
INDUSTRY